Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 9, 2015, Pages 1384-1390

  Omori Mizuno, Yoshie ^a   Nakayama, Nobuaki ^a   Inao, Mie ^a   Funyu, Junji ^b   Asabe, Shinichi ^c   Tomita, Kengo ^d   Nishikawa, Kou ^e   Hosoda, Yasuo ^f   Tanaka, Masahiko ^g   Hashimoto, Yoshiaki ^h   Yakabi, Koji ⁱ   Koshima, Yohei ^j   Mochida, Satoshi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Chichibu City Hospital   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE HOSPITAL   (Japan)

^e Ageo Chuo General Hospital   (Japan)

^f SAITAMA NATIONAL HOSPITAL   (Japan)

^g Kan Etsu Hospital   (Japan)

^h Department of Internal Medicine Aoki Hospital   (Japan)

ⁱ SAITAMA MEDICAL UNIVERSITY   (Japan)

^j SAITAMA RED CROSS HOSPITAL   (Japan)

more..

Author keywords

25(OH) D3; Alfacalcidol; Cholecalciferol; HCV; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCIFEDIOL; COLECALCIFEROL; PEGINTERFERON; PEGINTERFERON PLUS RIBAVIRIN; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; HYDROXYCOLECALCIFEROL; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; EDEMA; FEMALE; HEADACHE; HEPATITIS C VIRUS; HUMAN; INTERSTITIAL PNEUMONIA; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETINOPATHY; TREATMENT RESPONSE; UPREGULATION; VITAMIN BLOOD LEVEL; AGED; BLOOD; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; INTRAOCULAR DRUG ADMINISTRATION; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

ADMINISTRATION, OPHTHALMIC; AGED; ANTIVIRAL AGENTS; BIOMARKERS; CALCIFEDIOL; CHOLECALCIFEROL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYDROXYCHOLECALCIFEROLS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; UP-REGULATION;

EID: 84937822547     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12949     Document Type: Article

References (21)

1. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J. Gastroenterol. 2011; 17: 5184-5190.
2. Nimer A, Abu-Mouch S. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J. Gastroenterol. 2012; 18: 800-805.
3. Yokoyama S, Takahashi S, Kawakami Y etal. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J. Viral Hepat. 2014; 21: 348-356.
4. Gorai I, Hattori S, Tanaka Y, Iwaoki Y. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J. Bone Miner. Metab. 2012; 30: 349-358.
5. Scharla SH, Schacht E, Lempert UG. Alfacalcidol versus plain vitamin D in inflammation induced bone loss. J. Rheumatol. 2005; 76: 26-32.
6. Atsukawa M, Tsubota A, Shimada N etal. Efficacy of alfacalcidol on PEG-IFN/ribavirin combination therapy for elderly patients with chronic hepatitis C: a pilot study. Hepat. Mon. 2013; 13: e14872.
7. Hollis BW. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs 1, 2, 3. Am. J. Clin. Nutr. 2008; 88 (Suppl.): 507S-510S.
8. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-1109.
9. Akuta N, Suzuki F, Hirakawa M etal. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J. Med. Virol. 2009; 81: 452-458.
10. Prietl B, Treiber G, Thomas R, Amrein P, Amrein K. Vitamin D and immune function. Nutrients 2013; 5: 2502-2521.
11. Holick MF. Vitamin D deficiency. N. Engl. J. Med. 2007; 357: 266-281.
12. Holick MF, Binkley NC, Bischoff-Ferrari HA etal. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011; 96: 1911-1930.
13. Ross AC, Manson JE, Abrams SA etal. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 2011; 96: 53-58.
14. Imawari M, Akanuma Y, Itakura H, Muto Y, Kosaka K, Goodman DS. The effects of diseases of the liver on serum 25-hydroxyvitamin D and on the serum binding protein for vitamin D and its metabolites. J. Lab. Clin. Med. 1979; 93: 171-180.
15. Matsumura T, Kato T, Sugiyama N etal. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology 2012; 56: 1231-1239.
16. Su SS, He H, Kong LB etal. Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial. PLoS ONE 2014; 9: e93620.
17. Stone AE, Mitchell A, Brownell J etal. Hepatitis C virus core protein inhibits interferon production by a human plasmacytoid dendritic cell line and dysregulates interferon regulatory factor-7 and signal transducer and activator of transcription (STAT) 1 protein expression. PLoS ONE 2014; 9: e95627.
18. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C, Vitamin D. Modulator of the immune system. Curr. Opin. Pharmacol. 2010; 10: 482-496.
19. Gal-Tanamy M, Bachmetov L, Ravid A etal. An innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011; 54: 1570-1579.
20. Kondoh Y, Kato T, Kimura O etal. 1(OH) Vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients: case controlled trial. PLoS ONE 2013; 8: e63672.
21. Atsukawa M, Tsubota A, Shimada N etal. Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. Dig. Liver Dis. 2014; 46: 738-743.